FlyteHealth and Heartbeat Health unite to transform cardiometabolic care
FlyteHealth and Heartbeat Health unite to transform cardiometabolic care
FlyteHealth and Heartbeat Health unite to transform cardiometabolic care
FlyteHealth and Heartbeat Health have announced a strategic partnership to improve care for cardiometabolic and cardiovascular conditions. The collaboration introduces a bundled program that merges virtual cardiology with cardiometabolic support. Both companies aim to reduce healthcare costs and hospitalisations while boosting patient outcomes. The new program provides a single entry point for employers and payors, simplifying access to comprehensive care. It eliminates gaps in treatment, cuts down on fragmented services, and ensures smoother coordination between providers. By 2025, Heartbeat Health's virtual cardiology services already covered 27 US states before this partnership was unveiled.
Dr. Cheryl Pegus, CEO of FlyteHealth, emphasised that seamless, coordinated care leads to better adherence and health results. Dr. Jeff Wessler, CEO of Heartbeat Health, added that the partnership will deliver smarter care pathways. Together, the companies will manage risk more effectively while lowering hospital readmissions. Employers and payors benefit from streamlined implementation and unified reporting. The program also promises measurable returns on investment, addressing a major financial burden—cardiometabolic and cardiovascular conditions cost the US over $500 billion annually.
The partnership sets a new benchmark for integrated cardiometabolic and cardiovascular care across the US. It combines virtual cardiology and cardiometabolic support into one cohesive system. Patients, employers, and payors will now have access to a more efficient and outcome-driven model.
Biysk's Emergency Services Handle 1,783 Calls in One Week
From strokes to road accidents, Biysk's paramedics faced relentless pressure. Yet 113 calls were canceled—why did patients refuse help?
Abuja's new road project sparks debate as doctors decry failing hospitals
A shiny new road divides Abuja—while doctors warn lives are at risk in crumbling hospitals. Who gets priority in Nigeria's capital?
Heartseed loses Novo Nordisk backing for groundbreaking heart failure therapy
A promising cardiac treatment now stands alone. After Novo Nordisk's abrupt exit, Heartseed must navigate Phase 2 trials—and an uncertain future—without its pharma giant ally.
Groundbreaking trial tests twice-yearly injection for stubborn high blood pressure
Could a simple injection every six months transform hypertension care? Roche's $300M-backed trial seeks answers for patients who struggle with current treatments.